INTRODUCTION
Breast cancer has been shown to be a heterogeneous group of diseases at the molecular, pathological, and clinical level. Intrinsic subtypes of breast cancer, according to gene expres sion profiling, were first recognized by Perou et al. [1] . Many studies have shown that each subtype has different histo pathological presentations and prognostic outcomes [24] . However, gene expression profiling to identify breast cancer subtypes is not routinely used in the clinical setting due to its high cost. Each subtype has been revealed to have characteristic immunohistochemical (IHC) profiles according to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 expression status. Guidelines recommend treatment of breast cancer patients according to intrinsic subtype, as diagnosed by IHC staining of these surrogate markers [5, 6] .
Nonetheless, axillary lymph node metastasis remains a powerful prognostic factor that affects decisionmaking regar ding the use of adjuvant chemotherapy in early breast cancer.
Tamoxifen and trastuzumab have contributed to decreased recurrence and mortality in hormone receptorpositive and HER2positive breast cancer patients. However, cytotoxic chemotherapy remains the mainstay of treatment for many early breast cancer patients, especially nodepositive or ER and HER2negative patients. In these cases, it is not clear which patients will benefit more from chemotherapy: nodepositive early breast cancer or nodenegative patients with a poor prognostic subtype. In this study, we compared the recurrence rates in early breast cancer patients from two groups of patients with extremely different subtypes and nodal status, luminal Anode positive (pN1) type and triple negative breast cancer (TNBC)node negative (pN0) type, which are usually treated with chemotherapy and/or endocrine treatment.
METHODS

Patients
We retrospectively reviewed the medical records of 945 breast cancer patients who had curative surgery at our institution between 2003 and 2009. Of these patients, we excluded those with bilateral breast cancer, neoadjuvant chemotherapy, in situ carcinoma, tumor size less than 0.5 cm, stage III or IV breast cancer, metastatic carcinoma from other origin, and tumors of nonepithelial origin. Finally, 505 patients were included (Fig. 1 ). All pathologic records included primary tumor characteristics, such as tumor size, stage, tumor grade, ER, PR, and HER2 status, and Ki67 labeling index. Systemic adjuvant chemotherapy, endocrine treatment, and radiotherapy were performed in accordance with clinical guidelines. Pathologic staging was based on the 7th American Joint Committee on Cancer criteria [7] . Following surgery, patients underwent regular followups at 6month intervals during the first 5 years, followed by annual followup. Types of recurrence included local and regional recurrence, and distant metastasis.
Immunohistochemistry for surrogate markers
Tissue samples were fixed in neutral buffered formalin and embedded in paraffin. Fourmicrometerthick sections were immunostained for ER, PR, HER2, and Ki67. IHC was performed, following epitope retrieval, using a polymer detection system with antibodies against ER (clone SP1, Neomarkers, Lab Vision Co., Fremont, CA, USA; 1:500 dilution), PR (clone SP2, Neomarkers, Lab Vision Co.; 1:400 dilution), HER2 (clone CB11, Novocastra, Newcastle upon Tyne, UK; 1:500 dilution), and Ki67 (clone MIB1, Dako, Glastrup, Denmark; 1:1000 dilution) according to manufacturers' recommendations. Hormone receptors were defined as positive when ≥10% of nuclei showed positive staining. For HER2 staining, intense staining (3+) or amplification of the her2/neu gene using fluorescence in situ hybridization was regarded as positive. Ki67 was scored as the percentage of positively stained nuclei out of 1,000 cells counted. Breast cancers were divided into four subtypes, as per recommendations from the 13th International Breast Cancer Conference held at St Gallen, Switzerland in 2013: luminal A (ER positive, PR positive, Ki67 < 20%, HER2 negative), luminal B (ER positive, PR negative or Ki67 > 20% or HER2 positive), HER2 (ER negative, PR negative, HER2 positive), and TNBC (ER negative, PR negative, HER2 negative) [5] .
Statistical analysis
The patients were divided into two groups according to 945 
RESULTS
Clinicopathologic characteristics are described in Table 1 . Mean patient age was 51.6 years (range, 26-84 years). Path ologically node-negative patients comprised 71.9% of the total number of patients, and node positivity was seen in 28.1% of patients. Of the 505 patients included in the study, 44.6% had stage I breast cancer and 55.4% had stage II breast cancer. Hormone receptor positivity was seen in 70.1% of patients, and HER2 was positive in 20.4% of cases. Luminal A, luminal B, HER2, and triple negative subtypes, as defined using surrogate markers, accounted for 41%, 29.1%, 8.3%, and 21.6% of breast tumors, respectively.
Adjuvant chemotherapy was administered to 67.9% of patients. Chemotherapy regimens used included cyclophosphamide methotrexatefluorouracil (CMF), adriamycinbased regimens, and adriamycin plus taxane regimens. Adjuvant endocrine treatment was performed to 98% of hormone receptor-positive patients with tamoxifen or aromatase inhibitor. Adjuvant radiotherapy, including postmastectomy radiotherapy, was administered to 212 patients (42.0%), and nine patients with HER2 overexpression were treated with adjuvant trastuzumab for 1 year. The median followup duration for all patients was 89.5 months (range, 2-136 months). The 5year and 10year DFS for all cases were 90.6% and 86.3%, respectively.
Comparative analysis showed that there were more mas tectomies performed in the nodepositive group than in pathologic nodenegative patients (P = 0.006). Ductal carci noma as histologic type was more frequently found in node positive group than nodenegative group. Hormone receptor positivity was more prominent in nodepositive group (P = 0.041), however HER2 status and distribution of subtypes were not statistically different between two groups. Adjuvant chemotherapy was predominantly performed more in nodepositive group (P < 0.001). Adjuvant radiotherapy was performed more in nodenegative group (P < 0.001), because more breast conserving surgeries was done in nodenegative group. Other factors, such as age, tumor size, histologic grade, or adjuvant endocrine treatment did not show statistical differences ( Table 2 ). The nodepositive group was associated with significantly worse 5year and10year DFS compared to the nodenegative group (87% vs. 92.4%, 79.3% vs. 85.1%, P = 0.005) (Fig. 2A) ; the TNBC subtype showed the worst 5year and 10year DFS when compared to the luminal A subtype (82.4% vs. 94.1%, 79.9% vs. 92.9%, P = 0.010) (Fig. 2B) .
In luminal A and B disease, there were no statistically signi ficant differences in DFS between the pN0 and pN1 groups. However, in the HER2 and TNBC types, there were evident statistical differences in DFS between the pN0 and pN1 groups (Fig. 3A-D) . Analysis of hazard ratios for all 505 patients showed that the pN1 group was associated with 2.81fold increase in DFS compared to the pN0 group, and the TNBC subtype was associated with a 2.58fold increase in DFS compared to the Values are presented as number (%). HER2, human epidermal growth factor receptor 2; CMF, cyclo phosphamaide + methotrexate + 5fluorouracil (5FU).
a)
The chisquare test was used to identify the differences in varia bles between groups according to nodal status. luminal A subtype (Table 3) . In order to analyze the effect of lymphnode involvement and intrinsic subtypes on DFS in breast cancer patients, we performed subgroup analysis according to the following combination groups: luminal A with pN0, luminal A with pN1, TNBC with pN0, and TNBC with pN1.
As expected, the longest 5year DFS was seen in the luminal A-pN0 group (95.1%, P < 0.001). TNBC-pN0 were associated with shorter 5-year DFS (87.3% vs. 91.7%) and higher hazard ratio (2.64 vs. 2.06) when compared to the luminal ApN1 group. There were not statistically significant differences between the 10year DFS of the luminal ApN1 and TNBCpN0 groups (P = 0.618). The hazard ratio for recurrence of the TNBCpN1 group was 9.55 (Table 4) . While the hazard function for recurrence in the luminal ApN1 group showed a bimodal peak, the TNBC pN0 group was associated with a higher hazard, but most recurrences occurred within 60 months (Fig. 4) . We compared the clinicopathologic factors in following groups: TNBCpN0 group and luminal ApN1 group. Histologic grade 3 was more frequent in the TNBCpN0 group than in the luminal ApN1 group. No differences in age, surgical procedure, or tumor size were seen between two groups. The TNBC pN0 group included more stage I patients and was associated with less chemotherapy (77.4%; CMF 34.5%, adriamycin-based regimen 40.5%, adriamycin plus taxane regimen 2.4%) and endocrine treatment, due to the lack of lymph node involve ment and hormonereceptor negativity in this group. The luminal ApN1 group had more stage II patients and more frequent use of chemotherapy (93.4%; CMF 4.9%, adriamycin based regimen 14.8%, adriamycin plus taxane 73.8%) and endocrine treatment (Table 5) .
DISCUSSION
Involvement of axillary nodes has been the most important prognostic factor for breast cancer. Decisions regarding the use of adjuvant treatment in breast cancer have also largely been based on axillary node involvement. However, since the subtyping of breast cancer using gene expression profiling by Perou et al. [1] , heterogeneity in breast cancer has been widely studied. This led to recommendations for adjuvant treatment of early breast cancer according to ER and HER2 status since the 9th St Gallen International Breast Cancer Conference in 2005; the National Comprehensive Cancer Network guidelines also recommend similar subtypebased adjuvant treatment.
Many recent studies have shown prognostic differences between different intrinsic subtypes, but most of these studies have included only nodenegative breast cancer or both early and advanced breast cancer. In several studies of axillary node negative breast cancer, poor prognosis was associated with hormone receptornegative, HER2, and TNBC subtypes. A largescale study that included axillary nodenegative patients showed that overexpression of HER2 was poor prognostic factor for recurrence [8] . In studies of patients with nodenegative small tumors, <1 cm in size, the HER2 and TNBC subtypes were associated with shorter distant relapsefree survival compared to the luminal A subtype, which warrants the consideration of systemic chemotherapy in spite of small tumor size [9, 10] . However, the pattern of recurrence differs between different subtypes, irrespective of nodal status. Hormone receptor negative breast cancer shows of the highest rate of recurrence within 5 years, while hormone receptorpositive luminal type breast cancer shows lower hazards for recurrence within 5 years than hormone receptornegative breast cancer, and much lower but persistent risk for recurrence after 5 years [1113] . These studies demonstrate that followup duration of longer than 5 years is mandatory, and cumulative hazards and hazard ratios must both be taken into account when comparing the recurrence pattern between different subtypes.
We analyzed the recurrence pattern of the luminal ApN1 and TNBCpN0 groups in early breast cancer to compare the prog nostic power of nodal involvement and intrinsic subtypes. In the analysis of 5year DFS, luminal ApN1 was associate with longer DFS compared to the TNBC-pN0 group (91.7% vs. 87.3%, P = 0.618), in spite of its higher nodal stage. However, there were no statistical differences in 10year DFS between the two groups, and this is due to the late recurrence after 5 years in luminal A with pN1 group than TNBC with pN0 group as shown in hazard rate function graph.
Cytotoxic systemic chemotherapy is the mainstay of adju vant treatment in TNBC, but tumor size and node involve ment are currently the deciding factor for chemotherapy. Chemosensitivity tests were examined in various ways in vitro tests, however any specific regimen was not found to have selective effect according to breast cancer subtypes [14] . In clinical setting, classical CMF, anthracyclinebased regi mens and taxanecontaining regimens have all been used as adjuvant treatment for TNBC. However, the superiority of any one regimen is still a cause of debate. The classical CMF regimen has recently been suggested to be effective in TNBC. Moreover, it also has the advantage of a low toxicity profile and lower cost, compared to the other regimens [1517]. Rocca et al. [18] have reported that an epirubicincontaining regimen was associated with longer DFS and OS in early TNBC. The benefits of taxane in the treatment of TNBC type have also been reported in several [1921] . However, selective use of taxane is not routinely recommended in nodenegative early TNBC. Many of the studies carried out to analyze the efficacy of chemotherapy regimens in TNBC are retrospective in nature. Recently reported, large multiinstitutional studies have not recommended chemotherapy for all subtypes of T1abN0M0 breast cancer because they show excellent prognosis with or without chemotherapy [22] . Platinum compounds, poly ADP ribose polymerase (PARP) inhibitors, epidermal growth factor receptor (EGFR) antibodies, antiangiogenic drugs, and mammalian target of rapamycin (mTOR) inhibitors have been studied in large randomized controlled trials of recurrent or metastatic TNBC patients [2326] ; several phase III trials, analyzing the efficacy of adjuvant treatment in TNBC, are ongoing using various chemotherapeutic agents [27] .
In conclusion, intrinsic subtype is an independent prognostic factor for recurrence, and its prognostic power is similar to 
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